They should also have reiterated again that they would be filing...

They should also have reiterated again that they would be filing for the drug orphan application in the
March quarter 2019 .

I am sceptical as Cellmid was supposed to be human trials in early 2015 , which is one reason they were given such a valuation , investors were never  informed as to why it do not happen , very disrespectful .

2014

Cellmid (ASX:CDY) has selected Biotecnol SA subsidiary Rodon Biologics as the manufacturing partner for its humanised anti-midkine (MK) antibody CAB102 for clinical trials in multiple oncology indications.

Biotecnol has successfully completed numerous drug product and process development projects for 14 years.

This will save six months in ‘time to clinic’ for CAB102 with the clinical program on track for first in human studies in early 2015.

2015

Cellmid (ASX:CDY) is the subject of a research report from Netherlands and New York biotechnology and life sciences research firm Van Leeuwenhoeck.
Based on NPV based valuation, we believe that Cellmid is clearly undervalued at the current share price of AUD 0.03. Using our valuation model, the Company’s current total value is AUD 80 million, or AUD 0.086 per share.  , $ 1.72 after consolidation